The Consistency of Treatment Emergent AEs With the Known Safety Profiles for Belantamab Mafodotin and Pomalidomide
Suzanne Trudel, MD, MSC, FRCPC, of the University of Toronto and the Princess Margaret Cancer Centre in Toronto, discusses whether the treatment emergent adverse events (AEs) were consistent with the known safety profiles for belantamab mafodotin and pomalidomide.
Pharmacy Times® interviewed Suzanne Trudel, MD, MSC, FRCPC, an associate professor at the University of Toronto and a consultant in the Division of Medical Oncology and Hematology at the Princess Margaret Cancer Centre in Toronto, on one of her presentations at the 62nd ASH Annual Meeting and Exposition. The presentation is on the part 1 results of a dose finding study of belantamab mafodotin (belamaf) in combination with pomalidomide and dexamethasone for the treatment of relapsed/refractory multiple myeloma.
In this video, Trudel discusses whether the treatment emergent adverse events were consistent with the known safety profiles for belamaf and pomalidomide, and how these results affect the use of this combination treatment in the future.
